文献速递中毒与环境急症

芬太尼相关死亡病例中赛拉嗪与芬太尼血药浓度的关系评估

Evaluation of the relationship of xylazine and fentanyl blood concentrations among fentanyl-associated fatalities.
PubMed 文献 · Clin Toxicol (Phila) · 2024-02-14
一句话结论在芬太尼相关死亡者中,检出赛拉嗪者的死后芬太尼浓度中位数更高(17.0 vs 10.0 µg/L),芬太尼浓度>40 µg/L的比值比(OR)为2.41(95%CI 1.58-3.64)。

该回顾性队列研究分析了俄亥俄州富兰克林县验尸官办公室2019年1月1日至2023年3月16日期间所有芬太尼致死或促死病例,按是否同时检出赛拉嗪分为两组。共3052例芬太尼相关死亡,4.8%同时检出赛拉嗪;检出赛拉嗪的比例从2019年的2.7%线性上升至2022年的6.6%。检出赛拉嗪组的芬太尼浓度中位数为17.0 µg/L(四分位距7.9-27.0),未检出组为10.0 µg/L(四分位距5.6-18.0);芬太尼浓度>40 µg/L的比值比(OR)为2.41(95%CI 1.58-3.64)。作者推测赛拉嗪可能通过竞争性拮抗阿片类药物与μ阿片受体的部分结合,使暴露者耐受更高阿片剂量。

要点

  • 3052例芬太尼相关死亡中4.8%同时检出赛拉嗪,检出比例从2019年2.7%线性升至2022年6.6%。
  • 检出赛拉嗪者死后芬太尼浓度中位数17.0 µg/L(IQR 7.9-27.0),未检出者10.0 µg/L(IQR 5.6-18.0)。
  • 检出赛拉嗪者芬太尼浓度>40 µg/L的比值比(OR)为2.41(95%CI 1.58-3.64),高于未检出者。
  • 检出与未检出赛拉嗪的死亡者之间无有意义的人口学差异。
  • 研究期间年均726例芬太尼相关死亡,2020年峰值846例,此后下降。

适用人群与场景

  • 2019年1月1日至2023年3月16日期间美国俄亥俄州富兰克林县验尸官办公室报告的全部死亡病例,且芬太尼被判定为致死原因或促死因素。

诊断标准与关键阈值

  • 芬太尼相关死亡:芬太尼被判定为致死原因或促死因素。
  • 按死后毒理学是否同时检出赛拉嗪分为检出组与未检出组。

研究设计与关键结果

  • 研究类型:回顾性队列研究;研究期间共3052例芬太尼相关死亡。
  • 4.8%的芬太尼相关死亡者同时检出赛拉嗪。
  • 检出赛拉嗪与未检出赛拉嗪的死亡者之间无有意义的人口学差异。
  • 年均726例芬太尼相关死亡,2020年峰值846例,此后下降。
  • 芬太尼相关死亡中检出赛拉嗪的比例从2019年2.7%线性上升至2022年6.6%。
  • 检出赛拉嗪组芬太尼浓度中位数17.0 µg/L(IQR 7.9-27.0),未检出组10.0 µg/L(IQR 5.6-18.0)。
  • 检出赛拉嗪组芬太尼浓度>40 µg/L的比值比(OR)为2.41(95%CI 1.58-3.64),高于未检出组。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,赛拉嗪暴露者死亡前耐受更高阿片剂量的原因尚不清楚。
  • 作者推测,赛拉嗪可能通过竞争性拮抗阿片类药物与μ阿片受体的部分结合而产生上述现象。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Illicit fentanyl and fentanyl-analogs have produced a devastating increase in opioid fatalities in the United States. Increasingly, xylazine has been found in the illicit fentanyl supply. The role of xylazine in fentanyl intoxication remains unclear. We reviewed coroner records to evaluate trends and effects associated with xylazine in fentanyl-related fatalities.

METHODS: This is a retrospective cohort study of all deaths reported to the Franklin County Coroner's Office in Ohio from 1 January 2019 to 16 March 2023, in which fentanyl was determined causative or contributory to death. Cases identified as fentanyl-associated fatalities were separated into two groups based on whether or not xylazine was also detected.

RESULTS: There were 3,052 fentanyl-related fatalities during the study period. 4.8 percent of these decedents also tested positive for xylazine. There was no meaningful demographic difference between fentanyl-related fatalities in which xylazine was detected versus those without xylazine detected. There was a mean of 726 fentanyl-associated fatalities per year, with a peak of 846 deaths in 2020 and a decline thereafter. The percentage of fentanyl-related fatalities with xylazine detected increased in linear fashion from 2.7 percent in 2019 to 6.6 percent in 2022. The median fentanyl concentration was 17.0 µg/L (inter-quartile range: 7.9, 27.0) in cases with xylazine detected and 10.0 µg/L (inter-quartile range: 5.6, 18.0) without xylazine. The odds of a fentanyl concentration greater than 40 µg/L in cases with xylazine detected was more than twice as great (odds ratio: 2.41; 95 percent confidence interval: 1.58-3.64) than that in cases without xylazine detected.

CONCLUSIONS: Postmortem fentanyl concentrations were greater in cases with xylazine detected than those without xylazine detected. Though it is unclear why patients who were exposed to xylazine tolerated higher opioid doses prior to succumbing to death, we postulate that xylazine may act to competitively antagonize some degree of mu-opioid receptor binding by opioids.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Hays HL, Spiller HA, DeRienz RT, et al. Evaluation of the relationship of xylazine and fentanyl blood concentrations among fentanyl-associated fatalities. Clin Toxicol (Phila). 2024. PMID: 38353935. doi:10.1080/15563650.2024.2309326

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。